Perrigo (PRGO Quick QuotePRGO - Free Report) reported $988.6 million in revenue for the quarter ended September 2026, representing a year-over-year decline of 5.2%. EPS of $0.60 for the same period compares to $0.80 a year ago.

The reported revenue represents a surprise of -0.19% over the Zacks Consensus Estimate of $990.45 million. With the consensus EPS estimate being $0.56, the EPS surprise was +7.14%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Perrigo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Self Care: $612.7 million versus the two-analyst average estimate of $611.48 million.
• Net Sales- Specialty Sciences: $182.4 million versus $191.61 million estimated by two analysts on average.
• Net Sales- All Other: $112.7 million versus $103.89 million estimated by two analysts on average.
• Net Sales- Infant Formula: $80.7 million compared to the $78.7 million average estimate based on two analysts.

View all Key Company Metrics for Perrigo here>>>

Shares of Perrigo have returned +12.1% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.